TREATMENT OF BONE-RELATED CANCERS USING PLACENTAL STEM CELLS

• US 20110206645A1
• Filed: 01/25/2011
• Published: 08/25/2011
• Est. Priority Date: 01/26/2010
• Status: Active Grant

• Current Assignee: Celularity, Inc.
• Original Assignee: Anthrogenesis Corporation (Bristol-Myers Squibb Company)
• Inventors: YACCOBY, Shmuel, ABRAMSON, Sascha, ZHANG, Xiaokui
• Granted Patent: US 9,121,007 B2
• Time in Patent Office: Days
• US Class Current: 424/93.7
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/4545 containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
• CPC Class Codes: A61K 35/12 Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells vaccines or medicinal preparations containing antigens or antibodies A61K39/00
• CPC Class Codes: A61K 35/50 Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
• CPC Class Codes: A61K 9/0019 Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner non-active ingredients are additionally classified in A61K47/00
• CPC Class Codes: A61P 19/08 for bone diseases, e.g. rachitism, Paget's disease
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: C12N 2502/025 extra-embryonic cells, e.g. amniotic epithelium, placental cells, Wharton's jelly
• CPC Class Codes: C12N 2502/1142 Osteoclasts
• CPC Class Codes: C12N 2502/30 tumour cells
• CPC Class Codes: C12N 5/0605 Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly

Abstract

Provided herein are methods of suppression of proliferation and growth of cells of bone-related cancers, e.g., multiple myeloma or chondrosarcoma cells, using placental cells, e.g., the placental stem cells described herein, and populations of such placental cells. Also provided herein are methods of treating individuals having cells of a bone-related cancer.

Claims

1. A method of suppressing the proliferation of cells of a bone-related cancer, comprising contacting said cells of a bone-related cancer with a plurality of placental stem cells for a time sufficient for said placental stem cells to suppress proliferation of said cells of a bone-related cancer, as compared to a plurality of said cells of a bone-related cancer not contacted with placental stem cells,

wherein said placental stem cells are adherent to tissue culture plastic, are CD34⁻

, CD10⁺, CD105⁺ and CD200⁺ as detectable by flow cytometry, and are not trophoblasts, cytotrophoblasts or bone marrow-derived mesenchymal stem cells.

2. The method of claim 1, wherein said cells of a bone-related cancer are multiple myeloma cells.

3. The method of claim 1, wherein said cells of a bone-related cancer are chondrosarcoma cells.

4. The method of claim 1, wherein said cells of a bone-related cancer are bone cancer cells, neuroblastoma cells, osteosarcoma cells, Ewing sarcoma cells, chordoma cells, cells of a malignant fibrous histiocytoma of bone, prostate cancer cells, or cells of a fibrosarcoma of bone.

5. The method of claim 1, wherein said cells of a bone-related cancer are not prostate cancer cells.

6. The method of claim 1, wherein said placental cells are CD34⁻

, CD45⁻

, CD10⁺, CD90⁺, CD105⁺ and CD200⁺, as detectable by flow cytometry.

7. The method of claim 1, wherein said placental cells are CD34⁻

, CD45⁻

, CD10⁺, CD80⁻

, CD86⁻

, CD90⁺, CD105⁺ and CD200⁺, as detectable by flow cytometry.

8. The method of claim 1, wherein said contacting is performed in vitro.

9. The method of claim 1, wherein said contacting is performed in vivo.

10. The method of claim 9, wherein said contacting comprises administering said placental stem cells to a human individual comprising said cells of a bone related cancer.

11. The method of claim 10, wherein said contacting comprises administering said placental stem cells to said individual at or adjacent to a bone lesion caused by said bone-related cancer.

12. The method of claim 10, wherein said contacting comprises administering at least 1×

10⁸ of said placental stem cells to said individual.

13. The method of claim 1, wherein said placental cells suppress proliferation of said cells of a bone-related cancer by at least 50% compared to proliferation of an equivalent number of cells of a bone-related cancer in the absence of said placental cells.

14. A method of treating a human individual having a bone-related cancer, comprising administering to said individual a therapeutically effective amount of placental stem cells for a time sufficient for said placental stem cells to improve one or more symptoms of, or reduce the progression of, said bone-related cancer,

wherein said placental stem cells are adherent to tissue culture plastic, are CD34⁻

, CD10⁺, CD105⁺ and CD200⁺ as detectable by flow cytometry;

are not trophoblasts, cytotrophoblasts or bone marrow-derived mesenchymal stem cells, and have the capacity to differentiate into osteogenic or chondrogenic cells.

15. The method of claim 14, wherein said bone-related cancer is multiple myeloma.

16. The method of claim 14, wherein said bone-related cancer is chondrosarcoma.

17. The method of claim 14, wherein said bone-related cancer is bone cancer, neuroblastoma, osteosarcoma, Ewing sarcoma, chordoma, malignant fibrous histiocytoma of bone, prostate cancer, or fibrosarcoma of bone.

18. The method of claim 14, wherein said cells of a bone-related cancer are not prostate cancer cells.

19. The method of claim 14, wherein said placental stem cells are CD34⁻

, CD45⁻

, CD10⁺, CD90⁺, CD105⁺ and CD200⁺, as detectable by flow cytometry.

20. The method of claim 14, wherein said placental stem cells are CD34⁻

, CD45⁻

, CD10⁺, CD80⁻

, CD86⁻

, CD90⁺, CD105⁺ and CD200⁺, as detectable by flow cytometry.

21. The method of claim 14, wherein said placental stem cells are administered to said individual intravenously.

22. The method of claim 14, wherein said placental stem cells are administered to said individual at or adjacent to a bone lesion caused by said bone-related cancer.

23. The method of claim 14, comprising administering at least 1×

10⁸ placental cells to said individual.

24. The method of claim 14, wherein said placental cells suppress proliferation of cells of said bone-related cancer by at least 50% compared to proliferation of an equivalent number of cells of said bone-related cancer in the absence of said placental cells.